No different than their last shelf for $30M k rj just more available money.
In fact for me it certainly sends a strong signal that they are strongly contemplating launching full commercialization of at least some of the drugs in their pending pipeline themselves instead of partnership/licensing agreements like the one they have with PAR on FocalinXR k. With the key being a lot more profitability to IPCI's top & bottom lines if they are in fact planning on launching full commercialization themselves on several more of their pending drugs!
1 thing's for certain, the CEO didn't state on that recent television interview "that he's building IPCI to become the next Biovail, actually better than Biovail" without a strong plan already well in motion behind the scenes right tick tick tick tick tick;)